The firm's over-the-counter claim submission is delayed because it has been unable to find the required number of positive cases among asymptomatic people.
The firm said it intends to apply to obtain FDA Emergency Use Authorization and 510(k) clearance for a panel that detects respiratory targets in a single test.
The company's service revenues increased 157 percent to $457.9 million due to significant COVID-19 testing volumes, slightly offset by lower base business volumes.
The program will support Johns Hopkins' research into saliva testing and diagnostics and will help GBS form its commercialization strategy for two saliva-based tests.
